Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin as a Tuberculosis Treatment Adjunct
NCT04504851Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in pulmonary tuberculosis (TB) comparing Standard of Care with Standard of Care plus Rosuvastatin (2 arms). Primary endpoint: Time to culture conversion in Liquid Media at 8 weeks. Status: unknown.
02
Drugs
rosuvastatin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT04504851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504851.